Spero Therapeutics Announces Positive Phase 3 Clinical Trial Results From ADAPT-PO

published 11:46 pm ET September 8th, 2020

On August 8, Spero Therapeutics, Inc. (SPRO) announced positive topline results from its Phase 3 clinical trial. The ADAPT-PO clinical trial evaluates Spero’s oral antibiotic candidate tebipenem HBr for the treatment of complicated urinary tract (cUTI) infection and acute pyelonephritis (AP) in adults. The results showed that Spero’s oral treatment was statistically non-inferior to intravenous […]

September 8th, 2020 By Kim Newsletter 0 comments

Read More

0Comments

August 2020 Scorecard

published 1:09 pm ET September 8th, 2020

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 7 Number […]

September 8th, 2020 By Bojan Newsletter 0 comments

Read More

0Comments

July 2020 Scorecard

published 10:54 pm ET August 7th, 2020

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: July Scorecard Number of Signals 14 Percent Correct – Prev Close to 5-day Peak 93% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 10 Number […]

August 7th, 2020 By Bojan Newsletter 0 comments

Read More

0Comments

June 2020 Scorecard

published 11:57 pm ET July 7th, 2020

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: June Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 16% Other stats: Number of signals over $10/share 14 Number […]

July 7th, 2020 By Bojan Newsletter 0 comments

Read More

0Comments

Ekso Bionics Receives FDA Clearance of Robotic Exoskeleton for Acquired Brain Injuries

published 11:04 pm ET July 1st, 2020

Ekso Bionics Holdings, Inc. (EKSO) announced on June 25 that it received 501(k) clearance from the FDA to market its EksoNRTM robotic exoskeleton to patients with acquired brain injuries. The FDA previously cleared EksoNR for stroke and spinal cord injury rehabilitation in 2016, and it is the first such device cleared for use in patients with […]

July 1st, 2020 By Kim Newsletter 0 comments

Read More

0Comments

FDA Approves Lilly’s New Rapid-Acting Insulin, Lyumjev

published 11:07 pm ET June 16th, 2020

On June 15, the FDA approved Eli Lilly and Company’s (LLE) new drug, Lyumjev™. It is a new rapid-acting form of insulin designed to speed the absorption of insulin into the blood stream and resduce A1C levels. Lyumjev is a novel formulation of insulin lispro that controls high blood sugar after meals in adults with […]

June 16th, 2020 By Kim Newsletter 0 comments

Read More

0Comments

May 2020 Scorecard

published 9:09 pm ET June 7th, 2020

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: May Scorecard Number of Signals 22 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 15 Number […]

June 7th, 2020 By Bojan Newsletter 0 comments

Read More

0Comments

Argenx Reports Positive Phase 3 Clinical Trial Results

published 11:48 pm ET June 1st, 2020

On May 26, argenx (ARGX) reported positive Phase 3 clinical trial results from the ADAPT trial of efgartigimod. The ADAPT trial evaluates improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score for acetylcholine receptor-antibody positive (AChR-Ab+) generalized myasthenia gravis (gMG) patients. Respondents in the trial saw an improvement of at least two points […]

June 1st, 2020 By Kim Newsletter 0 comments

Read More

0Comments

Ultragenyx Reports Positive Initial Data on DTX401 Clinical Trial

published 11:28 pm ET May 15th, 2020

On May 15, Ultragenyx Pharmaceutical Inc. (RARE) presented positive initial data from all three cohorts in its DTX401 clinical trial. DTX401 is an adeno-associated virus-based gene therapy. It is undergoing clinical trials for the treatment of glycogen storage disease type 1a (GSD1a). All patients demonstrated significant cornstarch reductions over time and increases in time to […]

May 15th, 2020 By Kim Newsletter 0 comments

Read More

0Comments

April 2020 Scorecard

published 8:35 pm ET May 7th, 2020

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: April Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 92% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 9 Number […]

May 7th, 2020 By Bojan Newsletter 0 comments

Read More

0Comments